Tirzepatide vs Retatrutide
Last Updated: July 2026A current side-by-side review of tirzepatide and the investigational triple agonist retatrutide. Retatrutide now has positive Phase 3 results from several pivotal studies, while the direct TRIUMPH-5 comparison with tirzepatide remains active and has not reported results.
Receptor Pharmacology
Mechanism of Action Differences
Both molecules represent a shift away from single-receptor (GLP-1 only) therapies, but they utilize distinctly different mechanistic blueprints.
GLP-1 Receptor
Activates neural pathways regulating satiety and delays gastric emptying. Stimulates glucose-dependent insulin secretion.
GIP Receptor
Works synergistically with GLP-1 to enhance insulin sensitivity, buffer lipid storage in adipose tissue, and potentially mitigate nausea.
Glucagon Receptor
Promotes hepatic lipid clearance (lipolysis) and increases resting energy expenditure/thermogenesis, actively countering metabolic slowdown.
Data Visualizations
Current Clinical Endpoints
The first two charts summarize current results from separate tirzepatide and retatrutide trials. They are useful reference points, but differences in participants, study design, and duration prevent a head-to-head conclusion. The liver-fat chart is retained as clearly labelled historical Phase 2 context.
86.0%
Relative liver fat reduction
This result came from a retatrutide Phase 2 NAFLD substudy. It is useful historical context, although it provides no direct comparison with tirzepatide and cannot establish relative liver outcomes.
High-Level Summary
Endpoint Comparison Matrix
| Clinical Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual Agonist (GLP-1 + GIP) | Triple Agonist (GLP-1 + GIP + Glucagon) |
| Max Weight Reduction (Reported) | 22.5% efficacy-estimand mean (SURMOUNT-1, 15 mg, 72 weeks) | 28.3% efficacy-estimand mean (TRIUMPH-1, 12 mg, 80 weeks) |
| Metabolic Driver | Appetite suppression + insulin sensitivity | Appetite suppression + increased energy expenditure |
| Hepatic Focus | MASH resolution reported in SYNERGY-NASH | Up to 86% relative liver-fat reduction in a Phase 2 NAFLD substudy; no direct comparison |
| Development Stage | Extensive Phase 3 complete; regulatory approvals secured for obesity, T2D, OSA | Positive results reported from five Phase 3 studies; investigational and not approved, with additional studies ongoing |
| Heart Rate Note | Slight, transient increase typical of GLP-1s | Dose-related increases were reported in earlier trials and remain a monitored safety measure |
Clinical Tracks
Deep Dive by Indication
Tirzepatide: SURMOUNT-1
Jastreboff, A. M., et al. NEJM (2022) ↗Established the benchmark for modern obesity pharmacotherapy. At 72 weeks, the 15 mg dose resulted in a 20.9% mean weight reduction in adults with obesity (without diabetes). It proved that dual incretin action was vastly superior to diet/exercise alone.
Duration: 72 weeksRetatrutide: TRIUMPH-1 Phase 3
Lilly TRIUMPH-1 results (2026)At 80 weeks, the 12 mg group recorded a 28.3% efficacy-estimand mean reduction in body weight. Lilly also reported that 65.3% reached a BMI below 30 and 33.3% reached a BMI below 25.
Duration: 80 weeksThese percentages come from separate trials with different participants, methods, and durations, so they cannot establish which molecule performs better. TRIUMPH-5 is the direct Phase 3 comparison, and no results are posted yet.
Tirzepatide: SURPASS Program
Extensively proven in T2D. SURPASS-2 showed superiority over semaglutide 1mg, with HbA1c reductions up to 2.30%. It provides robust, reliable glycemic control and is a standard-of-care benchmark.
Retatrutide: TRANSCEND-T2D-1 Phase 3
At 40 weeks, retatrutide produced mean A1C reductions of up to 2.0% and mean body-weight reduction of up to 16.8% in adults with type 2 diabetes. The trial compared retatrutide with placebo, not tirzepatide.
Tirzepatide: SYNERGY-NASH
In SYNERGY-NASH, the highest tirzepatide dose was associated with MASH resolution without worsening fibrosis in 74% of participants at 52 weeks.
Retatrutide: NAFLD Sub-study
The Phase 2 NAFLD substudy reported up to 86% relative liver-fat reduction and a high proportion of participants reaching less than 5% liver fat at 48 weeks. These results describe retatrutide alone and do not establish how it compares with tirzepatide.
Clinical Protocols
Titration Schedules
Both molecules require careful step-up titration to mitigate gastrointestinal side effects (nausea, vomiting). Retatrutide utilizes a slightly shorter 4-step escalation to max dose compared to Tirzepatide's 5-step.
Comparative FAQ
Is Retatrutide just a stronger version of Tirzepatide?
No. While they share GLP-1 and GIP agonism, Retatrutide introduces a third mechanism (Glucagon receptor agonism). This fundamentally changes the metabolic profile by actively increasing energy expenditure and lipolysis, rather than relying primarily on appetite suppression and insulin regulation.
Why add Glucagon if it normally raises blood sugar?
Glucagon receptor activation can raise hepatic glucose output, while GLP-1 and GIP receptor activity supports glucose-dependent insulin secretion and other metabolic effects. Retatrutide is designed to balance all three pathways, and its net glycemic effect has been measured in clinical trials rather than inferred from the glucagon component alone.
Are the side effect profiles the same?
They are similar, primarily consisting of dose-dependent gastrointestinal issues (nausea, diarrhea, vomiting). However, due to the glucagon component, Retatrutide clinical trials noted a slightly more pronounced, transient increase in resting heart rate and isolated reports of mild skin hyperesthesia, though these generally resolved over time.
Do current results show which one is better?
No direct result is available yet. SURMOUNT-1 and TRIUMPH-1 enrolled separate groups and followed them for different lengths of time. TRIUMPH-5 is designed to compare retatrutide with tirzepatide directly, but ClinicalTrials.gov lists the study as active with no results posted.
Source Data Cross-References
- Tirzepatide SURMOUNT-1 (Obesity): Jastreboff, A. M., et al. (2022). NEJM. doi:10.1056/NEJMoa2206038
- Retatrutide TRIUMPH-1 and TRANSCEND-T2D-1: Lilly Phase 3 results (2026). Official results
- Retatrutide TRIUMPH-2 and TRIUMPH-3: Lilly Phase 3 results (2026). Official results
- Direct comparison in progress: TRIUMPH-5, NCT06662383. ClinicalTrials.gov record
- Tirzepatide SURPASS-2 (T2D): Frias, J. P., et al. (2021). NEJM. doi:10.1056/NEJMoa2107519
- Tirzepatide SYNERGY-NASH: Loomba, R., et al. (2024). NEJM. doi:10.1056/NEJMoa2401943
- Retatrutide NAFLD Sub-study: Sanyal, A. J., et al. (2024). Hepatology (EASL Presentation).